Clinical Trial Update: Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing single-agent carboplatin to carboplatin plus everolimus in advanced triple-negative breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Everolimus (everolimus)

Snippet

Sponsor: Amy Tiersten | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED